• Alternative explanation for troponin elevation
• Chronic Systolic Heart Failure with EF < 35%
• Age < 18 years-old
• Uncontrolled systemic bacterial or fungal infection
• Concomitant viral infection (eg, Influenza or other respiratory virus)
• Pregnant
• On mechanical circulatory support
• On mechanical ventilation for greater than 48 hours
• Resuscitated cardiac arrest
• known hypersensitivity to canakinumab or any of its excipients
• Neutrophil count <1000/mm3
• history of myeloproliferative disorder or active malignancy receiving chemotherapy
• known active tuberculosis or history of incompletely treated tuberculosis
• Current treatment with immunosuppressive agents
• Chronic prednisone use >10 mg/daily (for more than 3 weeks prior to admission)
• Has a history of solid-organ or bone marrow transplant
• Severe preexisting liver disease with clinically significant portal hypertension
• End-stage renal disease on chronic renal replacement therapy
• Enrollment in another investigational study using immunosuppressive therapy
• In the opinion of the investigator and clinical team, should not participate in the study
• If male and sexually active, must have documented vasectomy or must practice birth control and not donate sperm during the study and for 3 months after study drug administration
• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of investigational drug

Protocol

Yes. In English

Statistical plan

Yes

Data-sharing willing stated in the publication:

Not reported